Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2.

× No keyword cloud information.

40 in total

1. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.

Authors: Rupashree Sen; Karthika Natarajan; Jasjeet Bhullar; Suneet Shukla; Hong-Bin Fang; Ling Cai; Zhe-Sheng Chen; Suresh V Ambudkar; Maria R Baer
Journal: Mol Cancer Ther Date: 2012-07-09 Impact factor: 6.261

2. Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1.

Authors: H-B Qiu; W Zhuang; T Wu; S Xin; C-Z Lin; H-L Ruan; X Zhu; M Huang; J-L Li; X-Y Hou; Z-W Zhou; X-D Wang
Journal: Pharmacogenomics J Date: 2017-08-01 Impact factor: 3.550

3. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.

Authors: Paola Di Gion; Friederike Kanefendt; Andreas Lindauer; Matthias Scheffler; Oxana Doroshyenko; Uwe Fuhr; Jürgen Wolf; Ulrich Jaehde
Journal: Clin Pharmacokinet Date: 2011-09 Impact factor: 6.447

Review 4. Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up.

Authors: Sagar Agarwal; Anika M S Hartz; William F Elmquist; Björn Bauer
Journal: Curr Pharm Des Date: 2011 Impact factor: 3.116

5. Inhibition of multidrug resistance-linked P-glycoprotein (ABCB1) function by 5'-fluorosulfonylbenzoyl 5'-adenosine: evidence for an ATP analogue that interacts with both drug-substrate-and nucleotide-binding sites.

Authors: Shinobu Ohnuma; Eduardo Chufan; Krishnamachary Nandigama; Lisa M Miller Jenkins; Stewart R Durell; Ettore Appella; Zuben E Sauna; Suresh V Ambudkar
Journal: Biochemistry Date: 2011-04-13 Impact factor: 3.162

6. 2-Trifluoromethyl-2-Hydroxypropionamide Derivatives as Novel Reversal Agents of ABCG2 (BCRP)-Mediated Multidrug Resistance: Synthesis and Biological Evaluations.

Authors: Rishil J Kathawala; Tianwen Li; Danwen Yang; Hui-Qin Guo; Dong-Hua Yang; Xiang Chen; Changmei Cheng; Zhe-Sheng Chen
Journal: J Cell Biochem Date: 2017-04-25 Impact factor: 4.429

Review 7. ABCG2: a perspective.

Authors: Robert W Robey; Kenneth K K To; Orsolya Polgar; Marius Dohse; Patricia Fetsch; Michael Dean; Susan E Bates
Journal: Adv Drug Deliv Rev Date: 2008-12-16 Impact factor: 15.470

Review 8. Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors.

Authors: Christine Victoria Ichim
Journal: Stem Cells Transl Med Date: 2014-03-05 Impact factor: 6.940

9. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.

Authors: Suneet Shukla; Robert W Robey; Susan E Bates; Suresh V Ambudkar
Journal: Drug Metab Dispos Date: 2008-10-29 Impact factor: 3.922

10. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.

Authors: Karthika Natarajan; Jasjeet Bhullar; Suneet Shukla; Mehmet Burcu; Zhe-Sheng Chen; Suresh V Ambudkar; Maria R Baer
Journal: Biochem Pharmacol Date: 2012-12-19 Impact factor: 5.858